BioAge develops novel therapies for obesity and metabolic diseases by leveraging human aging biology and a discovery platform built on human longevity data. Its lead program, azelaprag, is an oral apelin receptor (APJ) agonist described as a potential first-in-class agent entering Phase 2 trials in combination with tirzepatide. In Phase 1b, azelaprag promoted muscle metabolism, increased energy expenditure, and prevented muscle atrophy in healthy older volunteers at bedrest; preclinical studies showed it doubled weight loss achieved on incretin drugs with improved body composition and muscle function. The company plans Phase 2 studies of azelaprag in combination with Lilly’s Zepbound (tirzepatide) and other incretins, with Zepbound studies expected to begin mid-2024 in collaboration with Eli Lilly’s Chorus. BioAge also maintains earlier-stage preclinical programs addressing pathways in metabolic aging. The announced financing will support these clinical programs and key upcoming data readouts.

Total raised

$170M

Funding rounds

1

Latest round

Series D

Latest activity

Feb 2024